Explore
Validate
LearnPA1-46126
antibody from Invitrogen Antibodies
Targeting: FOXP3
AIID, DIETER, IPEX, JM2, PIDX, SCURFIN, XPID
Western blot Immunocytochemistry
Immunoprecipitation Immunohistochemistry Flow cytometry Other assayAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [3]
- Immunocytochemistry [3]
- Immunohistochemistry [4]
- Flow cytometry [3]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA1-46126 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- FOXP3 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Prior to immunostaining paraffin tissues, antigen retrieval with sodium citrate buffer (pH 6.0) is recommended. Suggested positive control: mouse CD4+CD25+ T cells. Epitope affinity purified.
- Reactivity
- Human, Mouse, Rat, Bovine
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 1 mg/mL
- Storage
- -20°C or -80°C if preferred
Submitted references Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer.
p65/miR-23a/CCL22 axis regulated regulatory T cells recruitment in hepatitis B virus positive hepatocellular carcinoma.
Hamy AS, Derosa L, Valdelièvre C, Yonekura S, Opolon P, Priour M, Guerin J, Pierga JY, Asselain B, De Croze D, Pinheiro A, Lae M, Talagrand LS, Laas E, Darrigues L, Grandal B, Marangoni E, Montaudon E, Kroemer G, Zitvogel L, Reyal F
Oncoimmunology 2020;9(1):1677427
Oncoimmunology 2020;9(1):1677427
p65/miR-23a/CCL22 axis regulated regulatory T cells recruitment in hepatitis B virus positive hepatocellular carcinoma.
Li ZQ, Wang HY, Zeng QL, Yan JY, Hu YS, Li H, Yu ZJ
Cancer medicine 2020 Jan;9(2):711-723
Cancer medicine 2020 Jan;9(2):711-723
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Jurkat Tag cells were transfected with the expression vector (vector) or with the Foxp3 expression construct (Foxp3). 24 hours after transfection, cells were lysed and analyzed by Western blot with anti-Foxp3 antiserum (1:2000 dilution).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot detection of immunoprecipitated FOXP3 from HA-tagged FOXP3 transfected Jurkat T antigen cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of FOXP3 in Jurkat Tag cells. Samples were incubated in FOXP3 polyclonal antibody (Product # PA1-46126 using a dilution of 1:2000. Jurkat Tag cells were transfected with the expression vector (vector) or with the Foxp3 expression construct (Foxp3). 24 hours after transfection, cells were lysed and analyzed.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- The same transfectants were stained with anti-Foxp3 antibody and HRPO-conjugated (upper panel) or CY3-conjugated (lower panels) secondary antibody. Representative images (X100) are shown.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry analysis of FOXP3 in Transfectants. Samples were incubated in FOXP3 polyclonal antibody (Product # PA1-46126) followed by HRPO-conjugated (upper panel) or Cy3-conjugated (lower panels) secondary antibody. Representative images (x100) are shown.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry analysis of FOXP3 in Transfectants. Samples were incubated in FOXP3 polyclonal antibody (Product # PA1-46126) followed by HRPO-conjugated (upper panel) or Cy3-conjugated (lower panels) secondary antibody. Representative images (x100) are shown.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of FOXP3 in formalin-fixed paraffin-embedded tissue sections of human breast cancer. Samples were incubated in FOXP3 polyclonal antibody (Product # PA1-46126) using a dilution of 1:400. ACDs Integrated Co-Detection Workflow was performed using ACD RNAScope Probe. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue). CD8A mRNA (red) and FOXP3 protein (green).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of FOXP3 in formalin-fixed paraffin-embedded tissue sections of human breast cancer. Samples were incubated in FOXP3 polyclonal antibody (Product # PA1-46126) using a dilution of 1:200. ACDs Integrated Co-Detection Workflow was performed using ACD RNAScope Probe. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue). CD4 mRNA (red) and FOXP3 protein (green).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of FOXP3 in mouse spleen. Samples were incubated with FOXP3 polyclonal antibody (Product # PA1-46126) followed by using DAB with hematoxylin counterstain.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of FOXP3 in Tissue section of human tonsil. Samples were incubated in FOXP3 polyclonal antibody (Product # PA1-46126) using a dilution of 1:200 followed by HRP-labeled anti-rabbit IgG secondary antibody and DAB reagent. Nuclei of cells were counterstained with hematoxylin. This FoxP3 antibody generated an expected and a specific nuclear staining of FOXP3 in a subset of cells which are potentially the Treg cells.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Transfectants from A were permeabilized and stained with anti-Foxp3 antibody and FITC-conjugated secondary antibody. Cells were analyzed by flow cytometry. Percentage of positively stained cells are shown.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry of FOXP3 in SK-MEL-28 cells (blue) and a matched isotype control (orange). Samples were incubated in FOXP3 polyclonal antibody (Product # PA1-46126) using a dilution of 2.5 µg/mL for 30 minutes at room temperature followed by a Rabbit IgG (H+L) Cross-Adsorbed secondary antibody. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry of FOXP3 in Transfectants. Samples were incubated in FOXP3 polyclonal antibody (Product # PA1-46126) followed by FITC-conjugated secondary antibody. Percentage of positively stained cells are shown.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 Lower miR-23a expression was correlated with higher level of CCL22 expression and intratumoral Treg recruitment in HBV-positive HCC. A, HBV infection was associated with patient survival rate of HCC. Patients carrying HBV (n = 30) had significantly poorer prognosis than HBV - patients (n = 30). B, HBV - tissues (n = 30) and HBV + tissues (n = 30) expressed significantly lower level of miR-23a. C, HBV - tissues and HBV + tissues expressed significantly higher mRNA level of CCL22. D, HBV - tissues and HBV + tissues expressed significantly higher mRNA level of Foxp3. E, The protein levels of CCL22, Foxp3, p-p65, and p65 in normal control, HBV - and HBV + tumor tissues were evaluated by western blotting. F, The gray scale analysis of CCL22, Foxp3, p-p65, and p65 in normal control, HBV- and HBV+ tumor tissues. In ascending order: normal < HBV - < HBV + . G, Foxp3 signals (red) were colocalized with CD4 (green) signals in tissues. The ratios of Foxp3 + CD4 + cells were gradually increased from normal, HBV - HCC to HBV + HCC tissues. H. MiR-23a level was inversely correlated with CCL22 expression in HCC tissues, but not in normal control. I. MiR-23a level was inversely correlated with Foxp3 expression in HCC tissues, but not in normal control. Error bars represented mean +- SD. ** P < .01 and * P < .05. HBV + , HCC tissues with HBV infection. HBV - , HCC tissues without HBV infection. Normal, normal liver samples
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 7. Comedications influence TIL densities in mouse TNBC. Representative micrograph pictures of co-immunofluorescence of CD3 (green), CD4 (cyan), FOXP3 (magenta), and DAPI stain (blue) in AT3 tumors at sacrifice in mice treated with CTX, zolpidem (N05CF) or pantoprazole (A02BC) alone or combined together. Scale bar: 20 um (a). Spearman correlations between tumor sizes at sacrifice and CD3 + CD4 - cell density (b, left) and the ratio of CD3 + CD4 - cells/ CD3 + CD4 + FOXP3 + cells across six experimental groups comprising 6 mice/group (b, right). Bar graphs showing CD3 + CD4 - cell density in AT3-bearing mice treated with NaCl, N05CF or A02BC, (c, left), CTX, CTX + N05CF or CTX + A02BC (c, right). Data are shown as means +- SEM. P values were obtained using ANOVA test.
